November 21st, 2014
When it was announced last week that the Health Resources and Services Administration (HRSA) had withdrawn its long-awaited mega-reg, you may have momentarily breathed a sigh of relief. For months now, there’s been growing anxiety about what the mega-reg might address and how it might affect the 340B Program going forward. But HRSA’s latest action is not so much the end of the story as it is the start of a new chapter.
November 5th, 2014
If you’re confused over the status of the 340B orphan drug exclusion, and how it affects participating free-standing cancer hospitals (CAN), critical access hospitals (CAH), rural referral centers (RRC) and sole community hospitals (SCH), you’re not alone.
August 27th, 2014
Last year, Sentry provided support for a recently-published RAND report intended to clarify the 340B Program's purpose, value and extent. The report provides an insightful perspective on current utilization of the program and speculates on potential changes that may help shape the program's future.
August 25th, 2014
Sentry Data Systems announced today that they’re making available to pharmacies their industry-leading, proprietary 340B platform via a new offering called the Sentry 340B Technology Backbone.
August 7th, 2014
All hospitals with an active 340B ID as of July 1 are required to recertify to maintain their 340B eligibility. Failure to recertify annually will result in removal from the program.